Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

NCT04148898 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Leptomeningeal Metastasis
Non-small Cell Lung Cancer
EGFR Activating Mutation

Interventions

DRUG: Osimertinib
DRUG: Bevacizumab

Sponsor

Second Affiliated Hospital of Nanchang University

Collaborators

[object Object]